Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — J.P. Morgan 38th Annual Healthcare Conference 2020
20 slides from Angiodynamics's conference presentation, Jan 16, 2020
Slide 1: J.P. Morgan Healthcare Conference – AngioDynamics
J.P. MORGAN HEALTHCARE CONFERENCEAngioDynamicsJim Clemmer, President and CEOJanuary 16, 2020
Slide 2: Notice Regarding Forward-Looking Statements
Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strateg
Slide 3: Value Creation: AngioDynamics Transformation
VALUE CREATION AngioDynamics Transformation Evolving Total Addressable Markets Hi-Tech Platforms Supplies 0-3% Growth Rate 2-5% Growth Rate 3-7% Growth Rate 2018$ 1.3B 2020$ 1.9B 2024$ 3.2B 3
Slide 4: Focus on Innovative Medical Technologies
Focus on Innovative Medical Technologies Healthy Blood Flow to the Heart Expanded Treatment Options in Oncology Leveraging 3 main drivers to carve out our space in large, growing markets through innovative, disruptive technologies that treat patients with cancer, promote healthy blood flow and deliv
Slide 5: Auryon: ANY lesion type, length, location
ANY lesion type, ANY lesion length, ANY lesion location The first peripheral atherectomy technology that efficiently and repeatedly treats: Eximo is now Visit Auryon-PAD.com for more information. CONVENIENT SAFE EFFICIENT 5
Slide 6: Auryon Laser system: targeted, disciplined M&A
Targeted, disciplined M&A The Auryon Laser system uses a revolutionary, proprietary method of delivering a 355 nm wavelength combined with a short-pulse (10-25ns) providing a design to achieve superior clinical results. 6
Slide 7: Auryon first peripheral atherectomy technology
The Auryon system is the first peripheral atherectomy technology that efficiently and repeatedly treats any lesion type, any lesion length, at any lesion location.1 References: 1. Rundback J, Chandra P, Brodmann M, et al. Novel laser-based catheter for peripheral atherectomy: 6-month results from th
Slide 8: Auryon Atherectomy System clinical benefits
Auryon Atherectomy System is the first and only system capable of treating lesions in any location, whether highly calcified or thromboticOptimized laser parameters provide the power to treat calcified lesions above- (ATK) and below-the-knee (BTK), including below-the-ankleFDA 510(k) with ISR labeli
Slide 9: Auryon addressable markets and commercialization
2019 REVENUE 6.0% 5Yr CAGR 2019 PROCEDURES 157,400 47,600 $400M $120M AURYON ADDRESSABLE MARKETS 4.5% 5Yr CAGR *Millennium Research Group, Peripheral Vascular Devices 2017, 2019 market size estimates Laser Mechanical COMMERCIALIZATION FY20 FY21 Sales Headcount 12-18 26-32 Marketing Branding Implemen
Slide 10: AngioVac System and internal R&D
The AngioVac System allows physicians to remove unparalleled levels of clot burden through a minimally invasive procedure. Execution of internal R&D 10
Slide 11: The AngioVac System
Centrifugal Pump Console Waste Collection System Filter Saline AngioVac Cannula Reinfusion Cannula The AngioVac System The AngioVac System allows for the aspiration of embolic material such as fresh, soft thrombi or vegetation from the venous system. Utilizing a self-expanding, nitinol-reinforced fu
Slide 12: AngioVac platform for larger market segments
AngioVac provides a platform to move into Larger Market Segments S I M P L E C O M P L E X M O D E R A T E HIGH VOLUMELOW ASP C a t h e t e r D I r e c t e d T h r o m b o l y s I s P E R C U T A N E O U S T H R O M B E C T O M Y L a r g e M a t e r I a l A s p I r a t I o n Catheter Directed Thromb
Slide 13: AngioVac generations development
AngioVac Gen 1One shape – no directionalityNo Radio Opaque (RO) markersNo Over The Wire (OTW)Cutting and adapters AngioVac Gen 3Two shapesImproved flow ratesImproved flexibilityImproved navigation180-degree pre-curve is built for the RH AngioVac Gen 2Two shapesImproved RO markersOTW capabilityQuick
Slide 14: Clinical & Regulatory Pathway Expansion
Clinical & Regulatory Pathway Expansion A cancer therapy that increases a physician's options for patient treatment. 14
Slide 15: NanoKnife Irreversible Electroporation (IRE)
NanoKnife Irreversible Electroporation (IRE) The NanoKnife System uses 2 – 6 electrode probes to create a high-voltage electric field Cells within the electric field develop irreversible, nano-size pores, causing the cells to dieThis ablation is less traumatic than death caused by extreme heat or co
Slide 16: NanoKnife platform addresses unmet needs in large markets
NanoKnife provides a platform to address unmet needs in a number of large markets $32MANGO REV $162MCURRENT MARKET ~$590MTOTAL ADDRESSABLE MARKET LIVER, LUNG, KIDNEY, PANCREAS, PROSTATE Cancer Facts & Figures 2020American Cancer Society Cancer New Cases Annually Pancreas 57,600 Prostate 191,930 Live
Slide 17: NanoKnife regulatory and reimbursement timeline
Jan 2018 Oct 2018 Mar 2019 May 2019 Jun 2019 Oct 2019 Breakthrough Designation First Patient Enrolled FDA Nano 3.0 Clearance CPT Code Submission by SIR & ACS ICD 10 Codes (IRE Specific)Inpatient Payment Amounts (MS-DRG) IDE Approval ANTICIPATED FIRST 15 SITES 17
Slide 18: FY2020 first half results and full year guidance
FY2020First Half Results FY2020Full Year Guidance (Unchanged) Revenue $136.0M $280M – $286M GAAP Earnings Per ShareNon-GAAP Adjusted EPS $(0.11)$0.14 $(0.35) – $(0.40)$0.10 – $0.15 Gross Margin 58.6% 58% - 59% Adjusted EBITDA $13.7M $15M-20M Debt $0.0M $15.0M FY 2020 Six-Month Actuals and Full-Year
Slide 19: Summary: Growth Potential Powered by Three Key Drivers
SUMMARY Growth Potential Powered by Three Key Drivers M&A R&D Expansion of Clinical and Regulatory Pathways Meaningful transformation into larger, faster-growing markets with higher value medical technologies. 5 DEALS MONTHS 18 Innovative, proprietary portfolio of Medical Technologies that address u
Slide 20: Reconciliation Tables
Amounts in thousands Reconciliation Tables Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items.Deferred financing fees related to the old credit agreement were written off duri
AngioDynamics — J.P. Morgan 38th Annual Healthcare Conference 2020 on 6ix